Last $40.73 USD
Change Today -0.31 / -0.76%
Volume 173.6K
As of 8:10 PM 01/27/15 All times are local (Market data is delayed by at least 15 minutes).

acceleron pharma inc (XLRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/6/14 - $53.93
52 Week Low
09/9/14 - $23.61
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ACCELERON PHARMA INC (XLRN)

Related News

No related news articles were found.

acceleron pharma inc (XLRN) Related Businessweek News

No Related Businessweek News Found

acceleron pharma inc (XLRN) Details

Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of protein therapeutics for cancer and rare diseases. It develops sotatercept and ACE-536 that are in Phase II clinical trials to treat anemia and associated complications in patients with ß-thalassemia and myelodysplastic syndromes, and red blood cell disorders; and dalantercept, which is in Phase II clinical trials to inhibit blood vessel formation in tumors through the vascular endothelial growth factor pathway inhibitors. The company is also developing a protein therapeutic candidate, ACE-083, for a first-in-human clinical trial targeting diseases involving muscle loss. It has collaboration, license, and option agreement with Celgene Corporation. The company, formerly known as Phoenix Pharma, Inc., was founded in 2003 and is headquartered in Cambridge, Massachusetts.

80 Employees
Last Reported Date: 03/17/14
Founded in 2003

acceleron pharma inc (XLRN) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $400.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $380.7K
Senior Vice President and General Counsel
Total Annual Compensation: $319.3K
Compensation as of Fiscal Year 2013.

acceleron pharma inc (XLRN) Key Developments

Acceleron Pharma, Inc.(NasdaqGM:XLRN) added to NASDAQ Biotechnology Index

Acceleron Pharma, Inc. will be added to the NASDAQ Biotechnology Index.

Acceleron Pharma Inc. Appoints Francois Nader to the Board of Directors

Acceleron Pharma Inc. announced the appointment of Francois Nader to its Board of Directors. Dr. Nader has been President, Chief Executive Officer and a member of the Board of Directors of NPS Pharma since 2008. Dr. Nader currently serves as chairman of the Board of Trustees for BioNJ, New Jersey’s trade organization representing the biotechnology industry. He is also a Board member of the Biotechnology Industry Organization.

Acceleron Pharma, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:30 PM

Acceleron Pharma, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:30 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: John L. Knopf, Founder, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
XLRN:US $40.73 USD -0.31

XLRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for XLRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation XLRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 58.3x
Price/Book 7.9x
Price/Cash Flow NM Not Meaningful
TEV/Sales 50.6x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACCELERON PHARMA INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at